Is Aphria Inc (APHA) the Top Pick in the Drug Manufacturers - Specialty & Generic Industry?

Thursday, August 13, 2020 3:41 PM | InvestorsObserver Analysts

Aphria Inc (APHA) is near the top in its industry group according to InvestorsObserver. APHA gets an overall rating of 53. That means it scores higher than 53 percent of stocks. Aphria Inc gets a 84 rank in the Drug Manufacturers - Specialty & Generic industry. Drug Manufacturers - Specialty & Generic is number 136 out of 148 industries.

Overall Score - 53
APHA has an Overall Score of 53. Find out what this means to you and get the rest of the rankings on APHA!

What do These Ratings Mean?

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

What's Happening With Aphria Inc Stock Today?

Aphria Inc (APHA) stock is trading at $4.65 as of 3:23 PM on Thursday, Aug 13, a rise of $0.14, or 3.04% from the previous closing price of $4.51. The stock has traded between $4.50 and $4.69 so far today. Volume today is light. So far 3,076,335 shares have traded compared to average volume of 7,476,761 shares.

To screen for more stocks like APHA click here.

Share this article:

Related Companies

Upgrade to Premium and Analyze Stocks Like a Pro

50% Off All Subscriptions
InvestorsObserver Premium
InvestorsObserver Premium
InvestorsObserver Premium
Save up to 65% with annual

InvestorsObserver Premium

$ 20.75 $ 10.38 /month
$249 $124.50 billed annually

You May Also Like

Related Articles

Is Global Cord Blood Corp (CO) Stock a Great Value?

Denali Therapeutics Inc (DNLI) Stock Climbs 10.58% This Week; Should You Buy?

Should Replimune Group Inc (REPL) Stock be in Your Portfolio?

Should You Buy AcelRx Pharmaceuticals Inc (ACRX) Stock?

Sector Update: Health Care Stocks Slipping in Late Trade

Related Companies